Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes

Toxicology and Applied Pharmacology

Volumn 244, Issue 2, 2010, Pages 181-189

  Huen, Karen ^a   Harley, Kim ^a   Bradman, Asa ^a   Eskenazi, Brenda ^a   Holland, Nina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Enzymatic assay; Genetic control; Organophosphate; Paraoxonase; Pesticides; Pregnancy

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; PHENYLACETIC ACID;

ARTICLE; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME ASSAY; EPIGENETICS; FEMALE; GENE FREQUENCY; GENETIC REGULATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HISPANIC; HUMAN; OXIDATIVE STRESS; PREGNANCY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYLDIALKYLPHOSPHATASE; CHILD; COHORT STUDIES; ENZYME ACTIVATION; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; MEXICAN AMERICANS; PHOSPHORIC ACID ESTERS; POLYMORPHISM, GENETIC; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TIME FACTORS; YOUNG ADULT;

EID: 77950042981     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.12.031     Document Type: Article

References (50)

1. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 2004, 37:1304-1316.
2. Azarsiz E., Kayikcioglu M., Payzin S., Yildirim Sozmen E. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int. J. Cardiol. 2003, 91:43-51.
3. Barchowsky A., Klei L.R., Dudek E.J., Swartz H.M., James P.E. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med. 1999, 27:1405-1412.
4. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
5. Brackley M., Carro-Ciampi G., Stewart D.J., Lowden J.A., Ray A.K., Kalow W. Stability of the paraoxonase phenotyping ratio in collections of human sera with differing storage times. Res. Commun. Chem. Pathol. Pharmacol. 1983, 41:65-78.
6. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., Furlong C.E. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 2001, 68:1428-1436.
7. Carpintero A., Sanchez-Martin M.M., Cabezas-Delamare M.J., Cabezas J.A. Variation in serum arylesterase, beta-glucuronidase, cathepsin L and plasminogen activators during pregnancy. Clin. Chim. Acta 1996, 255:153-164.
8. Chen J., Kumar M., Chan W., Berkowitz G., Wetmur J.G. Increased influence of genetic variation on PON1 activity in neonates. Environ. Health Perspect. 2003, 111:1403-1409.
9. Cole T.B., Jampsa R.L., Walter B.J., Arndt T.L., Richter R.J., Shih D.M., Tward A., Lusis A.J., Jack R.M., Costa L.G., Furlong C.E. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 2003, 13:357-364.
10. Connelly P.W., Maguire G.F., Picardo C.M., Teiber J.F., Draganov D. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J. Lipid Res. 2008, 49:245-250.
11. Costa L.G., Cole T.B., Vitalone A., Furlong C.E. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin. Chim. Acta 2005, 352:37-47.
12. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 2005, 69:541-550.
13. Deakin S., Leviev I., Brulhart-Meynet M.C., James R.W. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem. J. 2003, 372:643-649.
14. Deakin S.P., James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Lond.) 2004, 107:435-447.
15. Pesticide Use Report, Annual 2007 2007, DPR, Department of Pesticide Regulation, California Environmental Protection Agency Sacramento, CA.
16. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid. Res. 2005, 46:1239-1247.
17. Elbarbry F., Alcorn J. Ontogeny of glutathione and glutathione-related antioxidant enzymes in rat liver. Res. Vet. Sci. 2009, 87:242-244.
18. Eskenazi B., Bradman A., Gladstone E., Jaramillo S., Birch K., Holland N. CHAMACOS, a longitudinal birth cohort study: lessons from the fields. J. Child. Health 2003, 1:3-27.
19. Eskenazi B., Harley K., Bradman A., Weltzien E., Jewell N.P., Barr D.B., Furlong C.E., Holland N.T. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ. Health Perspect. 2004, 112:1116-1124.
20. Ferre N., Camps J., Fernandez-Ballart J., Arija V., Murphy M.M., Ceruelo S., Biarnes E., Vilella E., Tous M., Joven J. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem. 2003, 49:1491-1497.
21. Franco R., Sanchez-Olea R., Reyes-Reyes E.M., Panayiotidis M.I. Environmental toxicity, oxidative stress and apoptosis: menage a trois. Mutat. Res. 2009, 674:3-22.
22. Furlong C.E., Holland N., Richter R.J., Bradman A., Ho A., Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genomics 2006, 16:183-190.
23. Gao P., He P., Wang A., Xia T., Xu Z., Niu Q., Guo L., Chen X. Effects of PCB153 on oxidative stress and 8-OHdG content induced by PBDE-47 in human neuroblastoma cells in vitro. Wei Sheng Yan Jiu 2009, 38:513-515.
24. Ginsberg G., Hattis D., Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol. Appl. Pharmacol. 2004, 198:164-183.
25. Harley K., Eskenazi B., Block G. The association of time in the US and diet during pregnancy in low-income women of Mexican descent. Paediatr. Perinat. Epidemiol. 2005, 19:125-134.
26. Holland N., Furlong C., Bastaki M., Richter R., Bradman A., Huen K., Beckman K., Eskenazi B. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ. Health Perspect. 2006, 114:985-991.
27. Hong Y.C., Park E.Y., Park M.S., Ko J.A., Oh S.Y., Kim H., Lee K.H., Leem J.H., Ha E.H. Community level exposure to chemicals and oxidative stress in adult population. Toxicol. Lett. 2009, 184:139-144.
28. Huen K., Harley K., Brooks J., Hubbard A., Bradman A., Eskenazi B., Holland N. Developmental Changes in PON1 Enzyme Activity in Young Children and Effects of PON1 Polymorphisms. Environ. Health Perspect. 2009, 117:1632-1638.
29. Huen K., Richter R., Furlong C., Eskenazi B., Holland N. Validation of PON1 enzyme activity assays for longitudinal studies. Clin. Chim. Acta 2009, 402:67-74.
30. Khersonsky O., Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44:6371-6382.
31. Kujiraoka T., Oka T., Ishihara M., Egashira T., Fujioka T., Saito E., Saito S., Miller N.E., Hattori H. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J. Lipid. Res. 2000, 41:1358-1363.
32. Landrigan P.J., Kimmel C.A., Correa A., Eskenazi B. Children's health and the environment: public health issues and challenges for risk assessment. Environ. Health Perspect. 2004, 112:257-265.
33. Li H.L., Liu D.P., Liang C.C. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J. Mol. Med. 2003, 81:766-779.
34. Li J., Wang X., Huo Y., Niu T., Chen C., Zhu G., Huang Y., Chen D., Xu X. PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. Genet. Med. 2005, 7:58-63.
35. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Lusis A.J., Furlong C.E. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779.
36. Li W.F., Sun C.W., Cheng T.J., Chang K.H., Chen C.J., Wang S.L. Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan. Toxicol. Appl. Pharmacol. 2009, 236:246-253.
37. Liao Y.T., Li W.F., Chen C.J., Prineas R.J., Chen W.J., Zhang Z.M., Sun C.W., Wang S.L. Synergistic effect of polymorphisms of paraoxonase gene cluster and arsenic exposure on electrocardiogram abnormality. Toxicol. Appl. Pharmacol. 2009, 239:178-183.
38. Neri M., Bonassi S., Knudsen L.E., Sram R.J., Holland N., Ugolini D., Merlo D.F. Children's exposure to environmental pollutants and biomarkers of genetic damage. I: overview and critical issues. Mutat. Res. 2006, 612:1-13.
39. Rainwater D.L., Rutherford S., Dyer T.D., Rainwater E.D., Cole S.A., Vandeberg J.L., Almasy L., Blangero J., Maccluer J.W., Mahaney M.C. Determinants of variation in human serum paraoxonase activity. Heredity 2009, 102:147-154.
40. Richter R.J., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9:745-753.
41. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 2006, 281:7657-7665.
42. Roy A.C., Loke D.F., Saha N., Viegas O.A., Tay J.S., Ratnam S.S. Interrelationships of serum paraoxonase, serum lipids and apolipoproteins in normal pregnancy. A longitudinal study. Gynecol. Obstet. Invest. 1994, 38:10-13.
43. Stenzel J., Worek F., Eyer P. Preparation and characterization of dialkylphosphoryl-obidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1192Q). Biochem. Pharmacol. 2007, 74:1390-1400.
44. Stephens J.C., Schneider J.A., Tanguay D.A., Choi J., Acharya T., Stanley S.E., Jiang R., Messer C.J., Chew A., Han J.H., Duan J., Carr J.L., Lee M.S., Koshy B., Kumar A.M., Zhang G., Newell W.R., Windemuth A., Xu C., Kalbfleisch T.S., Shaner S.L., Arnold K., Schulz V., Drysdale C.M., Nandabalan K., Judson R.S., Ruano G., Vovis G.F. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001, 293:489-493.
45. Stephens M., Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 2005, 76:449-462.
46. Tagliaferri S., Caglieri A., Goldoni M., Pinelli S., Alinovi R., Poli D., Pellacani C., Giordano G., Mutti A., Costa L.G. Low concentrations of the brominated flame retardants BDE-47 and BDE-99 induce synergistic oxidative stress-mediated neurotoxicity in human neuroblastoma cells. Toxicol. In Vitro 2010, 24:116-122.
47. Toescu V., Nuttall S.L., Martin U., Kendall M.J., Dunne F. Oxidative stress and normal pregnancy. Clin. Endocrinol. (Oxf.) 2002, 57:609-613.
48. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
49. Wigle D.T., Arbuckle T.E., Walker M., Wade M.G., Liu S., Krewski D. Environmental hazards: evidence for effects on child health. J. Toxicol. Environ. Health B Crit. Rev. 2007, 10:3-39.
50. Yang Y.J., Hong Y.C., Oh S.Y., Park M.S., Kim H., Leem J.H., Ha E.H. Bisphenol A exposure is associated with oxidative stress and inflammation in postmenopausal women. Environ. Res. 2009, 109:797-801.